IGF1 and COVID-19: Additional studies are warranted to further explore the potential therapeutic appropriateness of GH replacement therapy targeting the IGF-1 pathway in specific subgroups of COVID-19 patients with low IGF-1 levels who, as shown here, are at high risk of developing more severe disease.